Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Secondary Lymphoid Organs

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.

Scientific reports·2026

Same author

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Geburtshilfe und Frauenheilkunde·2026

Same author

Expert opinion : Radiotherapy in cutaneous squamous cell carcinoma: Recommendations from the DEGRO dermatooncology working group.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Same author

Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial.

BMJ open·2026

Same author

KORT - Knee osteoarthrosis radiotherapy trial: Protocol for a multidisciplinary pathway and a planned sham-controlled phase III trial of low-dose radiotherapy in knee osteoarthritis.

Osteoarthritis and cartilage open·2026

Same author

Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Search research articles

Related Experiment Video

Updated: Nov 10, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Pediatric classical Hodgkin lymphoma.

Andrea C Lo¹, Karin Dieckmann², Tanja Pelz³

¹Radiation Oncology, British Columbia Cancer and University of British Columbia, Vancouver, Canada.

Pediatric Blood & Cancer

|April 5, 2021

Summary

This summary is machine-generated.

Pediatric classical Hodgkin lymphoma (HL) treatment focuses on reducing long-term toxicities by tailoring therapy intensity based on risk. Current approaches in pediatric HL trials aim to minimize radiation and chemotherapy while improving outcomes.

Keywords:

Hodgkin lymphoma IMRT chemotherapy involved-site radiation therapy proton therapy radiation therapy treatment response

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Related Experiment Videos

Last Updated: Nov 10, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Area of Science:

Pediatric Oncology
Hematology
Cancer Treatment

Background:

Classical Hodgkin lymphoma (HL) has shifted from fatal to highly curable over the last century.
Minimizing long-term toxicities from radiation therapy (RT) and chemotherapy is a key goal in HL management.
Treatment intensity for classical HL is risk-stratified based on tumor stage, bulk, and B symptoms.

Purpose of the Study:

To review current pediatric classical HL treatment strategies.
To summarize approaches used in Children's Oncology Group (COG) and European Network Pediatric Hodgkin Lymphoma (EuroNet-PHL) trials.

Main Methods:

Risk classification using tumor stage, bulk, and B symptoms.
Utilizing chemotherapy response to guide radiation therapy (RT) decisions.
Implementing reduced RT volumes with conformal techniques in COG and EuroNet-PHL trials.
Employing standard or intensified chemotherapy regimens for higher-risk patients.

Main Results:

Transition to reduced RT volumes targeting high-risk sites.
Use of conformal RT techniques alongside chemotherapy.
Investigation of immunoregulatory drugs to mitigate intensified chemotherapy toxicities.

Conclusions:

Current pediatric classical HL management emphasizes risk-adapted therapy to balance efficacy and toxicity.
Ongoing trials explore novel agents like immunoregulatory drugs for improved treatment outcomes.
The focus is on reducing long-term side effects while maintaining high cure rates for pediatric HL.